Overview and Scope
Hepatitis drugs refer to medications that aggravate liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors can result in liver inflammation.
Sizing and Forecast
The hepatitis drugs market size has grown steadily in recent years. It will grow from $19.34 billion in 2023 to $20.28 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of the global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-based therapies for hepatitis.
The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $23.92 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Segmentation & Regional Insights
The hepatitis drugs market covered in this report is segmented –
1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents
2) By Route Of Administration: Oral, Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E
North America was the largest region in the hepatitis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6889&type=smp
Major Driver Impacting Market Growth
The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.
Key Industry Players
Major companies operating in the hepatitis drugs market report are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beijing Kawin Technology Share-Holding Co. Ltd., Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Agenus Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.
The hepatitis drugs market report table of contents includes:
1. Executive Summary
2. Hepatitis Drugs Market Characteristics
3. Hepatitis Drugs Market Trends And Strategies
4. Hepatitis Drugs Market – Macro Economic Scenario
5. Global Hepatitis Drugs Market Size and Growth
.
.
.
26. South America Hepatitis Drugs Market
27. Brazil Hepatitis Drugs Market
28. Middle East Hepatitis Drugs Market
29. Africa Hepatitis Drugs Market
30. Hepatitis Drugs Market Competitive Landscape And Company Profiles
Top Major Players:
- Gilead Sciences Inc
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
